AstraZeneca’s Tagrisso combination shows survival benefit in lung cancer trial
At 57% data maturity, the mortality risk was decreased by 23% for patients receiving the combination therapy.
08 September 2025
08 September 2025
At 57% data maturity, the mortality risk was decreased by 23% for patients receiving the combination therapy.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.